Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Living Cell Technologies ( (AU:1AI) ) just unveiled an update.
Algorae Pharmaceuticals has appointed David Gulland as Chief Operating Officer to lead its operational and commercial scale-up initiatives. Gulland’s extensive experience in pharmaceutical operations and leadership in scaling large businesses will be instrumental as Algorae expands its commercial division and AI-driven drug discovery efforts, strengthening its position in the pharmaceutical industry.
More about Living Cell Technologies
Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical development company focused on pioneering drug synergy discovery and development to address unmet medical needs. The company utilizes its proprietary AI platform, AlgoraeOS, which employs machine learning and deep neural networks to identify transformative drug combinations. Algorae collaborates with research institutions and pharmaceutical partners to accelerate the clinical translation of AI-predicted therapies.
Average Trading Volume: 4,270,350
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$16.87M
See more insights into 1AI stock on TipRanks’ Stock Analysis page.